These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35407443)

  • 1. ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.
    Takaya H; Namisaki T; Asada S; Iwai S; Kubo T; Suzuki J; Enomoto M; Tsuji Y; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
    Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis.
    Uemura M; Fujimura Y; Matsumoto M; Ishizashi H; Kato S; Matsuyama T; Isonishi A; Ishikawa M; Yagita M; Morioka C; Yoshiji H; Tsujimoto T; Kurumatani N; Fukui H
    Thromb Haemost; 2008 Jun; 99(6):1019-29. PubMed ID: 18521503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia.
    Ishikawa M; Uemura M; Matsuyama T; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Tsujimoto T; Takimura C; Fujimura Y; Fukui H
    Alcohol Clin Exp Res; 2010 Feb; 34 Suppl 1():S25-33. PubMed ID: 19094193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure.
    Takaya H; Namisaki T; Enomoto M; Kubo T; Tsuji Y; Fujinaga Y; Nishimura N; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
    Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis.
    Morioka C; Uemura M; Matsuyama T; Matsumoto M; Kato S; Ishikawa M; Ishizashi H; Fujimoto M; Sawai M; Yoshida M; Mitoro A; Yamao J; Tsujimoto T; Yoshiji H; Urizono Y; Hata M; Nishino K; Okuchi K; Fujimura Y; Fukui H
    Scand J Gastroenterol; 2008; 43(11):1387-96. PubMed ID: 18609162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis.
    Enomoto M; Takaya H; Namisaki T; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Inoue T; Matsumoto M; Yoshiji H
    Hepatol Res; 2022 Apr; 52(4):390-400. PubMed ID: 34964539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.
    Kubo M; Sakai K; Hayakawa M; Kashiwagi H; Yagi H; Seki Y; Hasegawa A; Tanaka H; Amano I; Tomiyama Y; Matsumoto M
    J Thromb Haemost; 2022 Jul; 20(7):1589-1598. PubMed ID: 35352474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.
    Ko S; Okano E; Kanehiro H; Matsumoto M; Ishizashi H; Uemura M; Fujimura Y; Tanaka K; Nakajima Y
    Liver Transpl; 2006 May; 12(5):859-69. PubMed ID: 16528712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.
    Asada S; Namisaki T; Kaji K; Takaya H; Kubo T; Akahane T; Kawaratani H; Nishimura N; Takeda S; Masuda H; Shibamoto A; Inoue T; Iwai S; Tomooka F; Tsuji Y; Fujinaga Y; Kitagawa K; Mitoro A; Sato S; Matsumoto M; Yoshiji H
    Dig Dis Sci; 2024 Mar; 69(3):851-869. PubMed ID: 38244124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure.
    Takaya H; Yoshiji H; Kawaratani H; Sakai K; Matsumoto M; Fujimura Y; Fukui H
    Biomed Rep; 2017 Sep; 7(3):277-285. PubMed ID: 28894574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.
    Tsujii N; Nogami K; Matsumoto M; Yoshizawa H; Takase T; Tanaka I; Sakai T; Fukuda K; Hayakawa M; Sakai K; Isonishi A; Matsuura K; Fujimura Y; Shima M
    Thromb Res; 2019 Jul; 179():1-10. PubMed ID: 31055186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
    Takaya H; Namisaki T; Shimozato N; Kaji K; Kitade M; Moriya K; Sato S; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
    World J Gastrointest Oncol; 2019 May; 11(5):424-435. PubMed ID: 31139312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.
    Takaya H; Kawaratani H; Kubo T; Seki K; Sawada Y; Kaji K; Okura Y; Takeda K; Kitade M; Moriya K; Namisaki T; Mitoro A; Matsumoto M; Fukui H; Yoshiji H
    Hepatol Res; 2018 Feb; 48(3):E52-E60. PubMed ID: 28628948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.
    Horii M; Uemura S; Uemura M; Matsumoto M; Ishizashi H; Imagawa K; Iwama H; Takeda Y; Kawata H; Nakajima T; Fujimura Y; Saito Y
    Heart Vessels; 2008 Sep; 23(5):301-7. PubMed ID: 18810578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
    Takaya H; Namisaki T; Moriya K; Shimozato N; Kaji K; Ogawa H; Ishida K; Tsuji Y; Kaya D; Takagi H; Fujinaga Y; Nishimura N; Sawada Y; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
    World J Gastroenterol; 2020 Dec; 26(45):7232-7241. PubMed ID: 33362379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
    Molvarec A; Rigó J; Bõze T; Derzsy Z; Cervenak L; Makó V; Gombos T; Udvardy ML; Hársfalvi J; Prohászka Z
    Thromb Haemost; 2009 Feb; 101(2):305-11. PubMed ID: 19190814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.
    Uemura M; Fujimura Y; Ko S; Matsumoto M; Nakajima Y; Fukui H
    Int J Hepatol; 2011; 2011():759047. PubMed ID: 21994870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.